Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Maastricht University Medical Center |
---|---|
Information provided by: | Maastricht University Medical Center |
ClinicalTrials.gov Identifier: | NCT00626938 |
Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.
Condition |
---|
Sarcoidosis |
Study Type: | Observational |
Study Design: | Case-Only, Cross-Sectional |
Official Title: | Proteomics as a Tool for Biomarker Detection in Sarcoidosis |
Blood will be collected from all participants, but all samples will be stored anonymously.
Estimated Enrollment: | 1000 |
Study Start Date: | March 2005 |
Estimated Study Completion Date: | March 2011 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
sarcoidosis
sarcoidosis patients
|
controls
healthy volunteers and other interstitial lung disease (ILD) patients
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Patients visiting the out-patient clinic of the university hospital Maastricht.
Inclusion Criteria:
Exclusion Criteria:
Contact: Marjolein Drent, Professor | 0031-43-3874347 | m.drent@mumc.nl |
Contact: Petal Wijnen, MSc | petal.wijnen@mumc.nl |
Netherlands | |
Maastricht University Medical Centre | Recruiting |
Maastricht, Netherlands, 6202 AZ | |
Contact: Marjolein Drent, Prof., MD, PhD 0031-43-3876497 m.drent@mumc.nl | |
Contact: Petal AH Wijnen, MSc petal.wijnen@mumc.nl | |
Principal Investigator: Petal AH Wijnen, MSc |
Study Director: | Marjolein Drent, Prof, MD, PhD | University Hospital Maastricht, Departement of Respiratory Medicine |
Principal Investigator: | Otto Bekers, PhD | University Hospital Maastricht, Departement of Clinical Chemistry |
Principal Investigator: | Christine Voorter, PhD | University Hospital Maastricht, Departement of Tissue Typing |
Study Chair: | Marja P van Dieijen-Visser, Prof, MSc, PhD | University Hospital Maastricht, Departement of Clinical Chemistry |
Responsible Party: | University Hospital Maastricht, Dept. of Respiratory Medicine ( Prof. Dr. M. Drent ) |
Study ID Numbers: | MEC 04-145.11 |
Study First Received: | February 14, 2008 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00626938 |
Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
sarcoidosis protein profile CYP-450 TNF-alpha polymorphisms HLA |
Lymphatic Diseases Sarcoidosis Lymphoproliferative Disorders |